For the last several quarters, Gilead Sciences’ earnings calls have been colored by anticipation for the launch of the California drugmaker's long-acting HIV pre-exposure prophylaxis (PrEP) option. | ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...

Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...

NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the ...

Return to shareholders -- $1.4 billion was returned to shareholders as of fiscal Q3 2025 through dividends and share repurchases. Anticipated step-up in expenses -- Research and development, as well ...

Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for ...

In recent weeks, Gilead Sciences announced Health Canada's conditional approval of LYVDELZI (seladelpar) for primary biliary ...

Gilead Sciences said on Thursday its HIV drug sales rose 4% to $5.3 billion in the third quarter including $39 million for ...

Gilead Sciences (NASDAQ:GILD) has discontinued a Phase 1 trial for GS-1219, a long-acting subcutaneously delivered treatment ...

Debt Management: Gilead Sciences's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.27, the company relies more heavily on borrowed funds, indicating a higher level ...

FOSTER CITY - Gilead Sciences reported better-than-expected third quarter earnings on Wednesday, but shares fell 4% after the company’s revenue guidance disappointed investors despite raising its full ...